Concepedia

Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells

Te‐Chun Hsia, Chih‐Yen Tu, Yun‐Ju Chen, Ya-Ling Wei, Meng-Chieh Yu, Sheng-Chie Hsu, Shing-Ling Tsai, Wen-Shu Chen, Ming‐Hsin Yeh, Chia-Jui Yen,

Molecular Pharmacology · 2013 · 37 citations · 44 references

DOI

Concepts

References

44

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

, , +17

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

Stephen Johnston, John Pippen, Xavier Pivot et al. · Journal of Clinical Oncology · 2009 · 1K citations · Full text

, , +17

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

David Cameron, Michelle Casey, Michael F. Press et al. · Breast Cancer Research and Treatment · 2008 · 803 citations

, , +17

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 738 citations

, , +17

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Wenle Xia, Robert J. Mullin, Barry R. Keith et al. · Oncogene · 2002 · 669 citations

, , +16